Home
/
SAB Biotherapeutics, Inc.
/
Financials
/
Quarterly
SAB Biotherapeutics, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that SAB Biotherapeutics, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q2
2023
Jun 30, 2023
$85.5K
Aug 21, 2023
Q1
2023
Mar 31, 2023
$581.1K
May 15, 2023
Q2
2023
Jun 30, 2022
$6.35M
Aug 21, 2023
Q1
2023
Mar 31, 2022
$11.80M
May 15, 2023
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2024
$1.21M
Nov 14, 2025
Q2
2025
Jun 30, 2024
$263.1K
Aug 7, 2025
Q1
2025
Mar 31, 2024
$944.6K
May 9, 2025
Q3
2024
Sep 30, 2023
$1.27M
Nov 6, 2024
Q2
2024
Jun 30, 2023
$85.5K
Aug 8, 2024
Q1
2024
Mar 31, 2023
$581.1K
May 20, 2024
Q3
2023
Sep 30, 2022
$3.59M
Nov 13, 2023
Q2
2023
Jun 30, 2022
$6.35M
Aug 21, 2023
Q1
2023
Mar 31, 2022
$11.80M
May 15, 2023
Q3
2022
Sep 30, 2021
$14.68M
Nov 14, 2022
Q2
2022
Jun 30, 2021
$18.21M
Aug 10, 2022
Q1
2022
Mar 31, 2021
$16.93M
May 12, 2022
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$45.45M
Nov 14, 2025
Q2
2025
Jun 30, 2025
($10.11M)
Aug 7, 2025
Q3
2025
Jun 30, 2025
($10.11M)
Nov 14, 2025
Q2
2025
Mar 31, 2025
($5.20M)
Aug 7, 2025
Q3
2025
Mar 31, 2025
($5.20M)
Nov 14, 2025
Q1
2025
Mar 31, 2025
($5.20M)
May 9, 2025
Q3
2025
Sep 30, 2024
($10.35M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($7.34M)
Aug 7, 2025
Q3
2025
Jun 30, 2024
($7.34M)
Nov 14, 2025
Q3
2025
Mar 31, 2024
($5.03M)
Nov 14, 2025
Q2
2025
Mar 31, 2024
($5.03M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($5.03M)
May 9, 2025
Q3
2024
Sep 30, 2023
($5.10M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($6.88M)
Aug 8, 2024
Q3
2024
Jun 30, 2023
($6.88M)
Nov 6, 2024
Q1
2024
Mar 31, 2023
($7.35M)
May 20, 2024
Q3
2024
Mar 31, 2023
($7.35M)
Nov 6, 2024
Q2
2024
Mar 31, 2023
($7.35M)
Aug 8, 2024
Q3
2023
Sep 30, 2022
($7.08M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($4.78M)
Aug 21, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($12.68M)
Nov 14, 2025
Q2
2025
Jun 30, 2025
($9.73M)
Aug 7, 2025
Q1
2025
Mar 31, 2025
($10.77M)
May 9, 2025
Q3
2025
Sep 30, 2024
($11.31M)
Nov 14, 2025
Q2
2025
Jun 30, 2024
($10.20M)
Aug 7, 2025
Q1
2025
Mar 31, 2024
($11.39M)
May 9, 2025
Q3
2024
Sep 30, 2023
($5.32M)
Nov 6, 2024
Q2
2024
Jun 30, 2023
($6.48M)
Aug 8, 2024
Q1
2024
Mar 31, 2023
($7.40M)
May 20, 2024
Q3
2023
Sep 30, 2022
($7.81M)
Nov 13, 2023
Q2
2023
Jun 30, 2022
($6.54M)
Aug 21, 2023
Q1
2023
Mar 31, 2022
($6.71M)
May 15, 2023
Q3
2022
Sep 30, 2021
($3.99M)
Nov 14, 2022
Q2
2022
Jun 30, 2021
($2.87M)
Aug 10, 2022
Q1
2022
Mar 31, 2021
$813.9K
May 12, 2022